Subcutaneous Daratumumab Monotherapy for Patients with High-Risk Smoldering Multiple Myeloma By Ogkologos - December 18, 2024 1043 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the AQUILA study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Seeing a Promising Future for Progress against Childhood Cancer September 16, 2021 This Common Antibiotic May Help Support Immune System in Cancer Patients... December 12, 2019 Outcomes From Second-Line Chemotherapy in Patients with Cholangiocarcinoma and FGFR2 Fusions July 1, 2020 Efficacy of Sunitinib in Patients with Metastatic Phaeochromocytomas and Paragangliomas March 12, 2024 Load more HOT NEWS After A Long And Dangerous Battle, Africa Has Been Declared Free... Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with... ‘Family Haven’ Gives Homeless Parents & Their Kids Hope And A... How Does Smoking Increase Your Cancer Risk? An Expert Q&A
